These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23925759)

  • 1. Risk factors for rare diseases can be risky to define: PML and natalizumab.
    Major EO; Douek DC
    Neurology; 2013 Sep; 81(10):858-9. PubMed ID: 23925759
    [No Abstract]   [Full Text] [Related]  

  • 2. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
    Schwab N; Schneider-Hohendorf T; Posevitz V; Breuer J; Göbel K; Windhagen S; Brochet B; Vermersch P; Lebrun-Frenay C; Posevitz-Fejfár A; Capra R; Imberti L; Straeten V; Haas J; Wildemann B; Havla J; Kümpfel T; Meinl I; Niessen K; Goelz S; Kleinschnitz C; Warnke C; Buck D; Gold R; Kieseier BC; Meuth SG; Foley J; Chan A; Brassat D; Wiendl H
    Neurology; 2013 Sep; 81(10):865-71. PubMed ID: 23925765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
    Pignolet B; Schwab N; Schneider-Hohendorf T; Bucciarelli F; Biotti D; Averseng-Peaureaux D; Outteryck O; Ongagna JC; de Sèze J; Brochet B; Ouallet JC; Debouverie M; Pittion S; Defer G; Derache N; Hautecoeur P; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Berger E; Pelletier J; Rico A; Zéphir H; Laplaud D; Wiertlewski S; Camu W; Thouvenot E; Casez O; Moreau T; Fromont A; Vukusic S; Papeix C; Vermersch P; Comabella M; Lebrun-Frenay C; Wiendl H; Brassat D;
    Neurology; 2016 Dec; 87(23):2491-2494. PubMed ID: 27815407
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Bucciarelli F; Scandella L; Ciron J; Biotti D; Lebrun-Frenay C; Mathey G; Clavelou P; Pelletier J; Ostkamp P; Meinl I; Windhagen S; Klotz L; Gross CC; Meuth SG; Deisenhammer F; Brassat D; Wiendl H;
    Neurology; 2019 Sep; 93(12):550-554. PubMed ID: 31439633
    [No Abstract]   [Full Text] [Related]  

  • 5. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Lieberman LA; Zeng W; Singh C; Wang W; Otipoby KL; Loh C; Plavina T; Gorelik L; Ransohoff RM; Cahir-McFarland E
    Neurology; 2016 Jan; 86(4):375-81. PubMed ID: 26718566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Baldwin KJ; Hogg JP
    Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab-induced PML: can the beast be tamed?
    Hohlfeld R
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC; Hecht EM
    Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
    Schwab N; Schneider-Hohendorf T; Wiendl H
    Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab therapy for multiple sclerosis.
    Derfuss T; Kuhle J; Lindberg R; Kappos L
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.